News | July 30, 2025
Novartis India posts Q1 FY26 net profit at Rs. 27.62 Cr
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Subscribe To Our Newsletter & Stay Updated
